BCL2/MDM2 Inhibitor Combo Effective in AML.
The BCL2 inhibitor venetoclax plus the MDM2 inhibitor idasanutlin may be effective in treating relapsed/refractory acute myeloid leukemia. In a phase Ib trial, 35.9% of patients who received the combination had a response; side effects were manageable.